Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis

Saved in:
Bibliographic Details
Published in:British journal of haematology 2019-04, Vol.185 (2), p.382-386
Main Authors: Veletic, Ivo, Manshouri, Taghi, Newberry, Kate J., Garnett, Jeannine, Verstovsek, Srdan, Estrov, Zeev
Format: Article
Language:English
Subjects:
Aged
Biomarkers - blood
C-Reactive Protein - analysis
Case-Control Studies
Female
fibrocytes
Hematology
Humans
Kaplan-Meier Estimate
Male
Middle Aged
monocytes
Myelofibrosis
Pentraxins
pentraxin‐3
Plasma levels
primary myelofibrosis
Primary Myelofibrosis - blood
Primary Myelofibrosis - pathology
Prognosis
serum amyloid P
Serum Amyloid P-Component - analysis
Tumor Burden
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863
cites cdi_FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863
container_end_page 386
container_issue 2
container_start_page 382
container_title British journal of haematology
container_volume 185
creator Veletic, Ivo
Manshouri, Taghi
Newberry, Kate J.
Garnett, Jeannine
Verstovsek, Srdan
Estrov, Zeev
description
doi_str_mv 10.1111/bjh.15528
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2083708719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2202963202</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863</originalsourceid><addsrcrecordid>eNp1kb1OwzAYRS0EglIYeAFkiQWGUP_kxx2hAgpCggFmy0k-q66cpNhJSzcegWfkSTCkMCDhwR58fPRdX4SOKDmnYY3y-eycJgkTW2hAeZpEjMZ0Gw0IIVlESSz20L73c0IoJwndRXs8XMQspgPUPkLdOvVq6o-3d44XVvlKYQtLsB4XjXNgVQt4ZdoZbruq6RzOO1dCjVVd4mYJTlmLfeeWZqksNjVeqNYEp-_fLJyplFvjag220SZ3jTf-AO1oZT0cbs4her6-eppMo_uHm9vJxX1UcCFENAYtCHCSijTXMY-J4jnwgmgWopZMpZkohM5TrcoUYjVONNWgc5plpeCZSPkQnfbehWteOvCtrIwvwFpVQ9N5yUjgiMjoOKAnf9B5yFqH6SRjhI1THvZAnfVUEXJ4B1pu8klK5FcVMlQhv6sI7PHG2OUVlL_kz98HYNQDK2Nh_b9JXt5Ne-UnJpmVUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2202963202</pqid></control><display><type>article</type><title>Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><creator>Veletic, Ivo ; Manshouri, Taghi ; Newberry, Kate J. ; Garnett, Jeannine ; Verstovsek, Srdan ; Estrov, Zeev</creator><creatorcontrib>Veletic, Ivo ; Manshouri, Taghi ; Newberry, Kate J. ; Garnett, Jeannine ; Verstovsek, Srdan ; Estrov, Zeev</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.15528</identifier><identifier>PMID: 30074241</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Biomarkers - blood ; C-Reactive Protein - analysis ; Case-Control Studies ; Female ; fibrocytes ; Hematology ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; monocytes ; Myelofibrosis ; Pentraxins ; pentraxin‐3 ; Plasma levels ; primary myelofibrosis ; Primary Myelofibrosis - blood ; Primary Myelofibrosis - pathology ; Prognosis ; serum amyloid P ; Serum Amyloid P-Component - analysis ; Tumor Burden ; Tumors</subject><ispartof>British journal of haematology, 2019-04, Vol.185 (2), p.382-386</ispartof><rights>2018 British Society for Haematology and John Wiley &amp; Sons Ltd</rights><rights>Copyright © 2019 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863</citedby><cites>FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863</cites><orcidid>0000-0002-0697-1807 ; 0000-0002-1623-3613 ; 0000-0002-6912-8569</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30074241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Veletic, Ivo</creatorcontrib><creatorcontrib>Manshouri, Taghi</creatorcontrib><creatorcontrib>Newberry, Kate J.</creatorcontrib><creatorcontrib>Garnett, Jeannine</creatorcontrib><creatorcontrib>Verstovsek, Srdan</creatorcontrib><creatorcontrib>Estrov, Zeev</creatorcontrib><title>Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>C-Reactive Protein - analysis</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>fibrocytes</subject><subject>Hematology</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>monocytes</subject><subject>Myelofibrosis</subject><subject>Pentraxins</subject><subject>pentraxin‐3</subject><subject>Plasma levels</subject><subject>primary myelofibrosis</subject><subject>Primary Myelofibrosis - blood</subject><subject>Primary Myelofibrosis - pathology</subject><subject>Prognosis</subject><subject>serum amyloid P</subject><subject>Serum Amyloid P-Component - analysis</subject><subject>Tumor Burden</subject><subject>Tumors</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kb1OwzAYRS0EglIYeAFkiQWGUP_kxx2hAgpCggFmy0k-q66cpNhJSzcegWfkSTCkMCDhwR58fPRdX4SOKDmnYY3y-eycJgkTW2hAeZpEjMZ0Gw0IIVlESSz20L73c0IoJwndRXs8XMQspgPUPkLdOvVq6o-3d44XVvlKYQtLsB4XjXNgVQt4ZdoZbruq6RzOO1dCjVVd4mYJTlmLfeeWZqksNjVeqNYEp-_fLJyplFvjag220SZ3jTf-AO1oZT0cbs4her6-eppMo_uHm9vJxX1UcCFENAYtCHCSijTXMY-J4jnwgmgWopZMpZkohM5TrcoUYjVONNWgc5plpeCZSPkQnfbehWteOvCtrIwvwFpVQ9N5yUjgiMjoOKAnf9B5yFqH6SRjhI1THvZAnfVUEXJ4B1pu8klK5FcVMlQhv6sI7PHG2OUVlL_kz98HYNQDK2Nh_b9JXt5Ne-UnJpmVUQ</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Veletic, Ivo</creator><creator>Manshouri, Taghi</creator><creator>Newberry, Kate J.</creator><creator>Garnett, Jeannine</creator><creator>Verstovsek, Srdan</creator><creator>Estrov, Zeev</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0697-1807</orcidid><orcidid>https://orcid.org/0000-0002-1623-3613</orcidid><orcidid>https://orcid.org/0000-0002-6912-8569</orcidid></search><sort><creationdate>201904</creationdate><title>Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis</title><author>Veletic, Ivo ; Manshouri, Taghi ; Newberry, Kate J. ; Garnett, Jeannine ; Verstovsek, Srdan ; Estrov, Zeev</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>C-Reactive Protein - analysis</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>fibrocytes</topic><topic>Hematology</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>monocytes</topic><topic>Myelofibrosis</topic><topic>Pentraxins</topic><topic>pentraxin‐3</topic><topic>Plasma levels</topic><topic>primary myelofibrosis</topic><topic>Primary Myelofibrosis - blood</topic><topic>Primary Myelofibrosis - pathology</topic><topic>Prognosis</topic><topic>serum amyloid P</topic><topic>Serum Amyloid P-Component - analysis</topic><topic>Tumor Burden</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Veletic, Ivo</creatorcontrib><creatorcontrib>Manshouri, Taghi</creatorcontrib><creatorcontrib>Newberry, Kate J.</creatorcontrib><creatorcontrib>Garnett, Jeannine</creatorcontrib><creatorcontrib>Verstovsek, Srdan</creatorcontrib><creatorcontrib>Estrov, Zeev</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Veletic, Ivo</au><au>Manshouri, Taghi</au><au>Newberry, Kate J.</au><au>Garnett, Jeannine</au><au>Verstovsek, Srdan</au><au>Estrov, Zeev</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2019-04</date><risdate>2019</risdate><volume>185</volume><issue>2</issue><spage>382</spage><epage>386</epage><pages>382-386</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>30074241</pmid><doi>10.1111/bjh.15528</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0697-1807</orcidid><orcidid>https://orcid.org/0000-0002-1623-3613</orcidid><orcidid>https://orcid.org/0000-0002-6912-8569</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2019-04, Vol.185 (2), p.382-386
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_miscellaneous_2083708719
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)
subjects Aged
Biomarkers - blood
C-Reactive Protein - analysis
Case-Control Studies
Female
fibrocytes
Hematology
Humans
Kaplan-Meier Estimate
Male
Middle Aged
monocytes
Myelofibrosis
Pentraxins
pentraxin‐3
Plasma levels
primary myelofibrosis
Primary Myelofibrosis - blood
Primary Myelofibrosis - pathology
Prognosis
serum amyloid P
Serum Amyloid P-Component - analysis
Tumor Burden
Tumors
title Pentraxin‐3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A03%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentraxin%E2%80%903%20plasma%20levels%20correlate%20with%20tumour%20burden%20and%20overall%20survival%20in%20patients%20with%20primary%20myelofibrosis&rft.jtitle=British%20journal%20of%20haematology&rft.au=Veletic,%20Ivo&rft.date=2019-04&rft.volume=185&rft.issue=2&rft.spage=382&rft.epage=386&rft.pages=382-386&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.15528&rft_dat=%3Cproquest_cross%3E2202963202%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3888-9ef80e30686bf4340a3be3c0f2528d2a678c8fb6fad6e4a95f1fefb177d837863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2202963202&rft_id=info:pmid/30074241&rfr_iscdi=true